Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of e- ab sensor - based real-time diagnosis of serum procalcitonin level

Conditions: Sepsis

Summary: the purpose of this study is to develop a real-time diagnostic technique with e- ab sensor for serum pct level measurement will offer a test with lower cost, and increase the applicability of serum procalcitonin (pct) level in daily clinical practice.

sepsis is a clinical syndrome with complex interactions between microorganism, host immune, inflammatory and coagulation response. the mortality rate associated with septic shock is high, up to 40-70%. currently, the diagnosis of sepsis depends on microbial infection and systemic inflammatory response syndrome, which lacks sensitivity and specificity. accordingly, society of critical care medicine (sccm) offered new recommendations about the diagnosis of sepsis in 2001, which included the serum level of procalcitonin (pct). increased pct levels through the clinical course correlated with higher mortality in critically-ill patients. on the other hand, recent studies also showed pct levels could guide the antibiotic treatment in patients with sepsis or lower respiratory tract infection. besides usage in sepsis population, serum pct level could also be used for aids in diagnosis of bacterial infection and for guide of antibiotic treatment in acute exacerbation of chronic obstructive airway disease. however, current method of pct assay depends on the kryptor system developed by brahms, germany, with the functional sensitivity of 60 pg/ml. each assay costs 1300 nt dollars, which is too expensive for serial follow-up of serum pct levels. a real-time diagnostic technique with e- ab sensor for serum pct level measurement will offer a test with lower cost, and increase the applicability of serum pct level in daily clinical practice. here, the investigators conduct a study to develop a real-time diagnostic technique with e- ab sensor for serum pct level measurement in patients with sepsis.

Eligibility criteria:
inclusion criteria: * patients who are admitted to medical intensive care units exclusion criteria: * patients who refuse consent

Keywords: procalcitonin measurement
a study to evaluate the pharmacokinetics, safety, and tolerability of intravenous brivaracetam in subjects >= 1 month to < 16 years of age with epilepsy

Conditions: Epilepsy

Summary: the purpose of the study is to evaluate the pharmacokinetics (pk), safety, and tolerability of brivaracetam (brv) administered intravenously (iv) in subjects \>= 1 month to \< 16 years of age with epilepsy.


Eligibility criteria:
inclusion criteria: * male or female from \>= 1 month to \< 16 years of age. for subjects who are \< 1 year from birth and who were preterm infants, the corrected gestational age should be used for this entry requirement * weight \>= 3 kg (6.6 lbs) * diagnosis of epilepsy * acceptable candidate for venipuncture and intravenous (iv) infusion * treatment with \>=1 anti epileptic drug (aed; including brv) without a change of dose regimen for at least 7 days prior to screening * no treatment with vagus nerve stimulation (vns), or the subject is being treated with vns and the settings have been constant for \>=7 days prior to screening * for female subjects: not of childbearing potential, or of childbearing potential and not sexually active/negative pregnancy test, or of childbearing potential and sexually active/negative pregnancy test/uses medically acceptable contraceptive methods exclusion criteria: * subject has previously received iv brivaracetam (brv) in this study * subject is being treated with brv at a dose \>5mg/kg/day (rounded) or \>200mg/day for subjects with body weights \>40kg * subject requires or is likely to require a change in concomitant antiepileptic drug(s) (aed\[s\]), dose of concomitant aed(s), or formulation of aed(s) during the 7 days prior to the intravenous (iv) pharmacokinetic (pk) period * subject is likely, in the opinion of the investigator, to require rescue medication during the initiating oral brv (iob) treatment or iv pk periods * subject has experienced generalized convulsive status epilepticus in the 28 days prior to screening or during the screening period

Keywords: epilepsy brivaracetam briviact open-label pediatric intravenous
carpal tunnel release through mini transverse approach

Conditions: Carpal Tunnel Syndrome; Carpal Tunnel Release; Carpal Tunnel Surgery; Carpal Tunnel Transverse Approach; CTS

Summary: carpal tunnel release through dorsal wrist crease mini transverse incision, about 1.5 cm length.

carpal tunnel release through a small approach on the distal wrist crease, it is about 1.5 cm, the benefits of this technique is less surgical traumatic and more tender, it takes less time for rehabilitation, so the patient can work next day of operation, and it has very cosmetic and gentle scar in results and outcome.

Eligibility criteria:
inclusion criteria: * patients presented with carpal tunnel syndrome refractory to conservative treatment * participant cooperation sufficient to operate under local anesthesia exclusion criteria: * un controlled diabetes mellitus type 1 and 2 * patients with non controlled vascular hypertension * significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant. * myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization * patients with history of carpal tunnel release surgery failure

Keywords: cts carpal tunnel syndrome carpal tunnel release mini incision of carpal tunnel release cosmetic surgery of carpal tunnel syndrome endoscopic carpal tunnel surgery carpal tunnel release through mini transverse approach dr. sayed issa's approach ctrmta octr ectr open carpal tunnel release endoscopic carpal tunnel release syria cosmetic safety rehabilitation, complications surgery satisfaction
radial reload open lar case series

Conditions: Low Anterior Resection; Proctosigmoid Resection; Rectal Cancer

Summary: the purpose of this research study is to evaluate the safety and feasibility of the radial reload stapler during open lar for rectal cancer. the surgeon will complete questionnaires relating to the function of the device.


Eligibility criteria:
inclusion criteria: 1. the subject is able to understand and sign informed consent form. 2. the subject is between 18-85 years of age. 3. the subject is anticipated to undergo a resection of the rectum with anastomosis below the peritoneal reflection for the treatment of rectal cancer. 4. the subject is anticipated to undergo mobilization and stapling of the rectum through an open incision. exclusion criteria: 1. any female patient, who is pregnant, suspected pregnant, or nursing. 2. the participant is unable or unwilling to comply with the study requirements, follow-up schedule. 3. the participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.

Keywords: rectal cancer stapler
small coronary artery treated by taxus liberté registry in japan

Conditions: Stable Angina Pectoris; Unstable Angina Pectoris

Summary: the utilization of paclitaxel-eluting coronary stents in small vessel diseases is effective in reducing both repeat revascularization and major adverse cardiac events within two year follow-up. to evaluate the procedural, short and long term clinical outcomes of the taxus liberte™ paclitaxel-eluting coronary stent in small coronary arteries of ≤ 2.5 mm in the reference vessel diameter.


Eligibility criteria:
inclusion criteria: 1. age ≥20 years and are able to undergo cabg 2. females who are not pregnant 3. patients who present with angina symptoms or myocardial ischemia 4. patients available for post-procedural observation and coronary angiography at 24 months 5. patients who have signed patient informed consent 6. lesion which is eligible for only one 2.5mm paclitaxel-eluting stent 7. de novo lesion or non-stented restenosed lesion exclusion criteria: 1. patients contraindicated for antiplatelet therapy or anticoagulant therapy 2. patients with significant allergic reaction to contrast medium 3. chronic total occlusion 4. lesion with timi0 5. lesion which is needed more than two stents 6. patients with chronic renal failure (scr\>3.0mg/dl) -

Keywords: taxus liberté small coronary artery disease paclitaxel-eluting stent
prevalence of auditory dysfunction and icu-acquired delirium following cardiac surgery with cardiopulmonary bypass: a prospective observational study

Conditions: Hearing Loss; Cardiac Surgery; Cardiopulmonary Bypass; Postoperative Cognitive Dysfunction; Delirium

Summary: audics-icu is a prospective observational aiming to evaluate the prevalence of auditive dysfunction following cardiac surgery. participants will undergo audiometric testings before and 3 months after cardiac surgery with cardiopulmonary bypass. furthermore, the study evaluates hearing loss-associated icu-acquired delirium after cardiac surgery with cardiopulmonary bypass.


Eligibility criteria:
inclusion criteria: * over 18 years old * undergoing non urgent cardiac surgery with cardiopulmonary bypass exclusion criteria: * pregnant * history of ear surgery * ear disease * inadequate understanding of the protocol
repetitive transcranial magnetic stimulation for failed back surgery syndrome

Conditions: Failed Back Surgery Syndrome

Summary: failed back surgery syndrome (fbss) is the term of persistent back and/or leg pain after surgery for lumbar disk herniation (ldh). repetitive transcranial magnetic stimulation (r-tms) is a technique that allows non-invasive and relatively painless stimulation of cerebral cortex. it can reduce the experience of chronic pain by using magnetic field to produce small electrical currents in the cortex.the aim of this study is to determine the effectiveness of r-tms treatment on patients with fbss.

methods: in this double-blinded, randomized, placebo-controlled trial, 20 patients (aged 34-65 years) clinically diagnosed as fbss, who had a history of surgery for ldh with persistent back and leg pain. patients in r-tms group received 5 hz of r-tms, as a 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions. r-tms applied with magventure device (magpro x100, denmark, 2009) and figure eight coil (mmc 140 parabolic, magventure). control group received sham r-tms with the same protocol. patients were assessed at baseline,after 5th and 10th sessions and 1 and 3 months after treatment. visual analogue scale (vas), dn-4 (douleur neuropathique-4 questionnaire), oswestry disability index (odi), beck depression inventory (bdi), pittsburgh sleep quality index (psqi) were used for evaluation.

Eligibility criteria:
inclusion criteria: * aged 34-65 years * clinically diagnosed as fbss * history of surgery for ldh with persistent back and leg pain * patients with no root compression in postoperative magnetic resonance imaging of lumbar spine exclusion criteria: * epilepsy * stroke * head trauma * history of intracranial operation * cardiac pacemaker * pregnancy * postoperative lumbar root compression * neurologic deficits * prior physiotherapy for low back pain last 6 month

Keywords: repetitive transcranial magnetic stimulation back pain failed back surgery syndrome
a trial study of sgn-00101 in treating pediatric patients with recurrent respiratory papillomatosis

Conditions: Papilloma; Recurrent Respiratory Papillomatosis

Summary: recurrent respiratory papillomatosis (rrp) causes wart-like lesions along the throat area and can obstruct the airway or become malignant. the cause has been related to specific types of human papillomavirus (hpv). the purpose of the study is to assess the clinical effectiveness of a trial drug, sgn-00101, in children with rrp and also assess its safety.


Eligibility criteria:
inclusion criteria: * male or female between 2 and 18 yrs old, inclusive, who has documented rrp. * patients with documented rrp * subject is surgically debulked within 7 days before the first dose of sgn-00101. * subject has had at least 4 debulking surgeries for rrp, had no intersurgical intervals greater than 84 days during the period of the last 4 surgeries. * subject is free of life threatening or serious concomitant disorders other than the disease under study. * females of childbearing potential must have a negative pregnancy test and must be practicing an effective/appropriate method of birth control as determined by the investigator. exclusion criteria: * subject has disease or status that causes compromise of the immune system. * subject has a history of ionizing radiation therapy to the respiratory tract. * patient has used concomitant medications that may suppress the immune system. * subject has received any specific or non-specific immunotherapy intended as treatment for their rrp (i.e. mumps vaccine injected intralesionally) within 9 months prior to week 0 of this study. * subject has participated in a past study with sgn-00101 * pregnancy and lactation.

Keywords: hpv papilloma
virtual reality application for pain and anxiety reduction during cystoscopy

Conditions: Pain; Anxiety

Summary: the aim of this research is to conduct a two-group randomized controlled intervention study to determine the effect of virtual reality applications on pain and anxiety during cystoscopy. the study population will consist of patients who have applied to the urology outpatient clinic of a university hospital for cystoscopy. the study sample will be composed of patients who volunteer to participate in the study and meet the criteria during the planned dates of the research. data will be collected using a 'personal information form' created by the researcher through a literature review, the 'visual analog scale' (vas) for assessing pain, and the 'state anxiety inventory' (sai) for assessing anxiety.


Eligibility criteria:
inclusion criteria: * being literate, * being conscious, * ability to understand and speak turkish and not have hearing or visual impairment, * agreeing to participate in the research. exclusion criteria: * having a diagnosed psychiatric and mental illness, * patients diagnosed with epilepsy (due to the risk of virtual reality glasses triggering epileptic seizures), * patients who do not want to continue the study
prognostic value for predicting outcome using functional near-infrared spectroscopy in stroke rehabilitation

Conditions: Stroke

Summary: to investigate the prognostic value of functional near-infrared spectroscopy (fnirs) in stroke rehabilitation with serial measurements.

serial measurements (immediately after being transferred to rehabilitation department \[t0\], at discharge from inpatient rehabilitation \[t1\], and follow up at one to three months from stroke onset \[t3\]) using functional near-infrared spectroscopy (fnirs) was done in all participants. the primary outcome was the outcome prediction rate using fnirs parameter and clinical parameters. secondary outcomes were as follows: fnirs activation pattern, laterality index, functional connectivity, fugl-meyer score, modified barthel index, , brunnstrom stage, box and block test, grip strength (handgrip, pinch grip, lateral prehension, three-jaw chuck), modified ashworth scale (wrist flexor and extensor spasticity, elbow flexor, and extensor spasticity, long finger flexor spasticity), modified rankin scale score, functional ambulation category, glasgow coma scale, neglect evaluation battery, korean version western aphasia battery, and scale for the assessment and rating of ataxia. the changes in the fnirs measurements and clinical parameters will be analyzed and also the correlation between the two will be analyzed to identify the prognostic value of fnirs.

Eligibility criteria:
inclusion criteria: * age 18 or above. * diagnosed as stroke (infarction/hemorrhage) with imaging studies. * participants who have given consent after listening to the full explanations of this study. * able to understand the contents of this study and is able to sign to the written consent by his/herself. * a legal representative has given written consent for those who meet the inclusion criteria but is unable to understand and agree by themselves due to impaired cognition, a legal representative. exclusion criteria: * traumatic brain injury. * unable to perform simple commands (motor task during fnirs scan) due to impaired cognition. * current symptoms are caused by diseases other than stroke (e.g., dementia, parkinson's disease) * participants with any symptoms that may hinder the compliance or evaluation (e.g., delirium and agitation) process. * participants with any uncontrolled disorders.
prevalence of dynamic instability among football players in the uae: a cross-sectional study

Conditions: Football Players

Summary: the purpose of this study is to determine dynamic instability prevalence in united arab emirates football players.


Eligibility criteria:
inclusion criteria: * male * 16-24 years . exclusion criteria: * previous injury in lower extremities
phase iii/seroquel sr bipolar depression monotherapy - us

Conditions: Affective Psychosis, Bipolar; Depression, Bipolar; Manic-Depressive Psychosis; Psychoses, Manic-Depressive

Summary: the purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (seroquel®) in the treatment of patients with acute bipolar depression for 8 weeks. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * documented diagnosis of bipolar 1 disorder or bipolar 11 disorder * outpatient status at enrollment exclusion criteria: * patients with \>8 mood episodes during the past 12 years * use of prohibited medications * substance or alcohol abuse or dependence * current suicide risk or suicide attempt within last 6 months.

Keywords: bipolar disorder bipolar depression, manic depression seroquel seroquel sr quetiapine fumarate
home-based hiit to improve crc survivorship: feasibility and relationship with novel surrogate biomarkers of crc recurrence

Conditions: Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colonic Neoplasms; Colonic Cancer; Rectal Neoplasms; Rectal Cancer

Summary: this 12-week, exercise study will assess the feasibility of a home-based high-intensity interval training (hiit) program among colorectal cancer survivors and explore the impact of home-based hiit compared to a standard home-based moderate-intensity continuous aerobic exercise program on physical outcomes linked with survival from colorectal cancer and surrogate blood markers of colorectal cancer recurrence. hiit is a type of aerobic exercise that includes short bursts (i.e. 1-4 minutes) of vigorous exercise followed by longer periods of moderate to lower intensity exercise (i.e. 1-10 minutes). participants in this study will be randomly assigned into a personalized home based exercise program - either high-intensity interval training (hiit) or moderate-intensity continuous aerobic exercise (mice). this pilot study will provide us with preliminary evidence for a larger trial aimed to compare the effectiveness of these two different types of home-based exercise programs on physical outcomes linked with survival, quality of life, and surrogate blood markers of colorectal cancer recurrence.


Eligibility criteria:
inclusion criteria: 1. patients who are no more than five years post resection and/or adjuvant therapy for stage ii-iii colorectal cancer (crc). 2. age 19-75 years old. 3. engaging in less than 90 minutes per week of structured moderate- or vigorous-intensity aerobic exercise in the past three months 4. no known cardiovascular, metabolic or renal disease, and no signs/symptoms suggestive of cardiovascular, metabolic, or renal disease. 5. must be able to read, speak and understand english 6. willing to complete two assessment sessions (at baseline and 12 weeks). 7. willing to engage in moderate- or vigorous-intensity aerobic exercise at home and use mobile health technology to track exercise adherence to the exercise prescription. 8. able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. 9. have regular access to a smart phone and willing to download a free application for device tracking exclusion criteria: 1. functional limitations requiring a walker, scooter, or wheelchair. 2. clinically evident recurrent disease. 3. resting blood pressure ≥140/90 at the time of baseline testing. 4. no access to smart phone and/or not willing download the device app
livalo acute myocardial infarction study

Conditions: Acute Myocardial Infarction

Summary: statins are usually used in ami patients due to its strong anti-lipidemic effect, pleiotropic effect and tolerable safety profiles. generally ami patients are prescribed many drugs concomitantly; there are some risks due to the drug interaction. especially, statins are reported to have many drug interactions, these might influence to therapeutic prognosis and safety in ami patients. this study is conducted to administer the non-cyp3a4 metabolized statin, pitavastatin to ami patients over 1 year, and the results will be compared with the other results from the kamir study which is expected to the large scale of ami patients using statins be enrolled. finally, from that comparison, we will investigate the influence of the statins metabolism by cyp3a4 to the therapeutic prognosis like death, major adverse cardiac events(mace), and major adr of statins like ck increase, myalgia.


Eligibility criteria:
inclusion criteria: * the patients who have taken pitavastatin since ami exclusion criteria: * none

Keywords: hydroxymethylglutaryl-coa reductase inhibitors
the effect of renal denervation on renal flow in humans

Conditions: Hypertension

Summary: many studies have studied the effect and safety of renal denervation. however, it remains unknown what the exact mechanism behind renal denervation is. it can be hypothesized that a difference in renal blood flow occurs after treatment. in the light of this ignorance, current study will investigate whether renal denervation leads to a difference in renal blood flow after treatment with renal denervation.


Eligibility criteria:
inclusion criteria: * individual is scheduled to undergo renal denervation as standard patient care for resistant hypertension. * individual is diagnosed with resistant hypertension. secondary causes and a white coat hypertension are actively excluded. * individual is ≥18 years of age. * individual agrees to have all study procedures performed, and is competent and willing to provide written informed consent to participate in this clinical study. exclusion criteria: * individual is excluded from treatment with prdn . * individual has an estimated glomerular filtration rate (egfr) of \<30ml/min/1.73m2, using the mdrd calculation. * individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques. * individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia or significant anaemia). * individual is pregnant, nursing or planning to be pregnant. * individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.